Tower Research Capital LLC (Trc) Nuvalent, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 323 shares of NUVL stock, worth $27,716. This represents 0.0% of its overall portfolio holdings.
Number of Shares
323
Previous 10,375
96.89%
Holding current value
$27,716
Previous $787,000
95.81%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding NUVL
# of Institutions
211Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.72 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$429 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$355 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$259 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$256 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.69B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...